Biomarin Pharmaceutical (BMRN) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to -$1.5 billion.
- Biomarin Pharmaceutical's Enterprise Value fell 5883.16% to -$1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.5 billion, marking a year-over-year decrease of 5883.16%. This contributed to the annual value of -$1.1 billion for FY2024, which is 595.04% down from last year.
- Latest data reveals that Biomarin Pharmaceutical reported Enterprise Value of -$1.5 billion as of Q3 2025, which was down 5883.16% from -$1.4 billion recorded in Q2 2025.
- In the past 5 years, Biomarin Pharmaceutical's Enterprise Value registered a high of -$930.4 million during Q3 2024, and its lowest value of -$1.5 billion during Q3 2025.
- Its 5-year average for Enterprise Value is -$1.2 billion, with a median of -$1.1 billion in 2023.
- In the last 5 years, Biomarin Pharmaceutical's Enterprise Value surged by 2830.61% in 2021 and then crashed by 5883.16% in 2025.
- Over the past 5 years, Biomarin Pharmaceutical's Enterprise Value (Quarter) stood at -$1.0 billion in 2021, then dropped by 27.39% to -$1.3 billion in 2022, then increased by 16.86% to -$1.1 billion in 2023, then decreased by 5.95% to -$1.1 billion in 2024, then dropped by 29.9% to -$1.5 billion in 2025.
- Its Enterprise Value was -$1.5 billion in Q3 2025, compared to -$1.4 billion in Q2 2025 and -$1.3 billion in Q1 2025.